THE Therapeutic Goods Administration (TGA) has approved Kimmtrak (tebentafusp) to treat unresectable or metastatic uveal melanoma in HLA-A*02:01 positive patients.
The medication will remain on the Black Triangle Scheme for five years from the date the product is first supplied in Australia.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jun 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jun 22
